These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35208536)

  • 1. The Expression and Prognostic Value of Cancer Stem Cell Markers, NRF2, and Its Target Genes in TAE/TACE-Treated Hepatocellular Carcinoma.
    Tseeleesuren D; Hsiao HH; Kant R; Huang YC; Tu HP; Lai CC; Huang SF; Yen CH
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208536
    [No Abstract]   [Full Text] [Related]  

  • 2. NRF2 Dysregulation in Hepatocellular Carcinoma and Ischemia: A Cohort Study and Laboratory Investigation.
    Ziv E; Zhang Y; Kelly L; Nikolovski I; Boas FE; Erinjeri JP; Cai L; Petre EN; Brody LA; Covey AM; Getrajdman G; Harding JJ; Sofocleous C; Abou-Alfa GK; Solomon SB; Brown KT; Yarmohammadi H
    Radiology; 2020 Oct; 297(1):225-234. PubMed ID: 32780006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization.
    Shin BS; Park MH; Jeon GS
    Acta Radiol; 2011 Apr; 52(3):331-5. PubMed ID: 21498371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma.
    Miraglia R; Pietrosi G; Maruzzelli L; Petridis I; Caruso S; Marrone G; Mamone G; Vizzini G; Luca A; Gridelli B
    World J Gastroenterol; 2007 Jun; 13(21):2952-5. PubMed ID: 17589945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation.
    Zeng Z; Ren J; O'Neil M; Zhao J; Bridges B; Cox J; Abdulkarim B; Schmitt TM; Kumer SC; Weinman SA
    BMC Cancer; 2012 Dec; 12():584. PubMed ID: 23216644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation.
    Zen C; Zen Y; Mitry RR; Corbeil D; Karbanová J; O'Grady J; Karani J; Kane P; Heaton N; Portmann BC; Quaglia A
    Liver Transpl; 2011 Aug; 17(8):943-54. PubMed ID: 21491582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
    Xu X; Gao D; Yuan X; Liu LI; Zhang X; Liang X; Chen S; Ai M; Chen BO; Shi D; Yang Z; Hoffman RM; Xu J
    Anticancer Res; 2019 Mar; 39(3):1129-1134. PubMed ID: 30842141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
    Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
    J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma.
    Ma XL; Jiang M; Zhao Y; Wang BL; Shen MN; Zhou Y; Zhang CY; Sun YF; Chen JW; Hu B; Gong ZJ; Zhang X; Cao Y; Pan BS; Zhou J; Fan J; Yang XR; Guo W
    Ann Surg Oncol; 2018 Jun; 25(6):1686-1694. PubMed ID: 29626309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations of telomere length and mtDNA copy number are associated with overall survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
    Bao D; Ba Y; Zhou F; Zhao J; Yang Q; Ge N; Guo X; Wu Z; Zhang H; Yang H; Wan S; Xing J
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):791-9. PubMed ID: 27558242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm.
    Su TS; Lu HZ; Cheng T; Zhou Y; Huang Y; Gao YC; Tang MY; Jiang HY; Lian ZP; Hou EC; Liang P
    BMC Cancer; 2016 Nov; 16(1):834. PubMed ID: 27809890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
    Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
    Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional polymorphisms in the NPAS2 gene are associated with overall survival in transcatheter arterial chemoembolization-treated hepatocellular carcinoma patients.
    Yuan P; Wang S; Zhou F; Wan S; Yang Y; Huang X; Zhang Z; Zhu Y; Zhang H; Xing J
    Cancer Sci; 2014 Jul; 105(7):825-32. PubMed ID: 24754267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
    Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
    [No Abstract]   [Full Text] [Related]  

  • 15. Transarterial injection of (131)I-lipiodol, compared with chemoembolization, in the treatment of unresectable hepatocellular cancer.
    Marelli L; Shusang V; Buscombe JR; Cholongitas E; Stigliano R; Davies N; Tibballs J; Patch D; Meyer T; Burroughs AK
    J Nucl Med; 2009 Jun; 50(6):871-7. PubMed ID: 19443599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiofrequency Ablation (RFA) Combined with Transcatheter Arterial Chemoembolization (TACE) for Patients with Medium-to-Large Hepatocellular Carcinoma: A Retrospective Analysis of Long-Term Outcome.
    Liu W; Xu H; Ying X; Zhang D; Lai L; Wang L; Tu J; Ji J
    Med Sci Monit; 2020 Jul; 26():e923263. PubMed ID: 32667906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
    Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
    BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.
    Xu W; Kwon JH; Moon YH; Kim YB; Yu YS; Lee N; Choi KY; Kim YS; Park YK; Kim BW; Wang HJ
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1507-15. PubMed ID: 24853275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
    Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
    Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
    Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
    Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.